Investigation of inhibition mechanism of chemokine receptor CCR5 by micro-second molecular dynamics simulations

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Salmas, Ramin Ekhteiari ^a   Yurtsever, Mine ^a   Durdagi, Serdar ^b  

^a ISTANBUL TECHNICAL UNIVERSITY   (Turkey)

^b BAHCESEHIR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; LIGAND; MARAVIROC; TRIAZOLE DERIVATIVE;

ALGORITHM; CHEMISTRY; CLUSTER ANALYSIS; DRUG EFFECTS; HUMAN; HYDROGEN BOND; METABOLISM; MOLECULAR DYNAMICS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; TIME FACTOR; VIRUS ENTRY;

ALGORITHMS; CLUSTER ANALYSIS; CYCLOHEXANES; HUMANS; HYDROGEN BONDING; LIGANDS; MOLECULAR DYNAMICS SIMULATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CCR5; TIME FACTORS; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 84940042486     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13180     Document Type: Article

References (73)

1. Pease J. E., & Horuk R. Chemokine receptor antagonists: Part 1. Expert Opin. Ther. Pat. 19, 39-58 (2009
2. Pease J. E., & Horuk R. Chemokine receptor antagonists: part 2. Expert Opin. Ther. Pat. 19, 199-221 (2009
3. Qin K., Dong C., Wu G., & Lambert N. A. Inactive-state preassembly of Gq-coupled receptors and Gq heterotrimers. Nat. Chem. Biol. 7, 740-747 (2011
4. de Voux A., Chan M. C., Folefoc A. T., Madziva M. T., & Flanagan C. A. Constitutively Active CCR5 Chemokine Receptors Differ in Mediating HIV Envelope-dependent Fusion. PLoS One 8, (2013
5. Palczewski K. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 289, 739-745 (2000
6. Wu B., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010
7. Cherezov V., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318, 1258-1265 (2007
8. Rasmussen S. G. F., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450, 383-387 (2007
9. Choe H.-W., et al. Crystal structure of metarhodopsin II. Nature 471, 651-655 (2011
10. Scheerer P., et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497-502 (2008
11. Rasmussen S. G., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011
12. Murphy P. M. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 54, 227-229 (2002
13. Gerard C., & Rollins B. J. Chemokines and disease. Nat. Immunol. 2, 108-115 (2001
14. Disease M. O. F., & Disease M. O. F. The Many Roles of Chemokines and Chemokine Receptors in Inflammation. Receptor 354, 610-621 (2006
15. Viola A., & Luster A. D. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48, 171-197 (2008
16. Kondru R., et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73, 789-800 (2008
17. Baba M., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA. 96, 5698-5703 (1999
18. Barré-Sinoussi F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983
19. Tan Q., et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-90 (2013
20. Freedman B. D., Liu Q.-H., Del Corno M., & Collman R. G. HIV-1 gp120 chemokine receptor-mediated signaling in human macrophages. Immunol. Res. 27, 261-276 (2003
21. Weissman D., et al. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389, 981-985 (1997
22. Wu Y., & Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog. 5, e1000520 (2009
23. Alkhatib G., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996
24. Napier K. B., Wang Z. X., Peiper S. C., & Trent J. O. CCR5 interactions with the variable 3 loop of gp120. J. Mol. Model. 13, 29-41 (2007
25. Kothandan G., Gadhe C. G., & Cho S. J. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: A combined in silico study. PLoS One 7, e32864 (2012
26. Gadhe C. G., Kothandan G., & Cho S. J. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach. J. Biomol. Struct. Dyn. 31, 1251-76 (2013
27. Kondru R., et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73, 789-800 (2008
28. Tamamis P., & Floudas C. A. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS One 9, e95767 (2014
29. Eswar N., et al. Comparative protein structure modeling using MODELLER. Curr. Protoc. Protein Sci. Chapter 2, Unit 2.9 (2007
30. Madhavi Sastry G., Adzhigirey M., Day T., Annabhimoju R., & Sherman W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided. Mol. Des. 27, 221-234 (2013
31. Bas D. C., Rogers D. M., & Jensen J. H. Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins Struct. Funct. Genet. 73, 765-783 (2008
32. Lomize M. A., Lomize A. L., Pogozheva I. D., & Mosberg H. I. OPM: Orientations of proteins in membranes database. Bioinformatics 22, 623-625 (2006
33. Humphrey W., Dalke A., & Schulten K. VMD: Visual molecular dynamics. J. Mol. Graph. 14, 33-38 (1996
34. Jorgensen W. L., Chandrasekhar J., Madura J. D., Impey R. W., & Klein M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926 (1983
35. Nelson M. T., et al. NAMD: a Parallel, Object-Oriented Molecular Dynamics Program. Int. J. High Perform. Comput. Appl. 10, 251-268 (1996
36. Huang J., & Mackerell A. D. CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. J. Comput. Chem. 34, 2135-2145 (2013
37. Vanommeslaeghe K., Raman E. P., & MacKerell A. D. Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges. J. Chem. Inf. Model. 52, 3155-3168 (2012
38. Pearson K. L. III On lines and planes of closest fit to systems of points in space. London, Edinburgh, Dublin Philos. Mag. J. Sci. 2, 559-572 (1901
39. Hotelling H. Analysis of a complex of statistical variables into principal components. J. Educ. Psychol. 24, 417-441 (1933
40. Ichiye T., & Karplus M. Collective motions in proteins: a covariance analysis of atomic fluctuations in molecular dynamics and normal mode simulations. Proteins 11, 205-217 (1991
41. García A. Large-amplitude nonlinear motions in proteins. Phys. Rev. Lett. 68, 2696-2699 (1992
42. Grant B. J., Rodrigues A. P. C., ElSawy K. M., McCammon J. A., & Caves L. S. D. Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22, 2695-2696 (2006
43. Rother K. Introduction to PyMOL. Methods Mol. Biol. Clift. Nj 635, 0-32 (2005
44. R Development Core Team R. R: A Language and Environment for Statistical Computing. R Found. Stat. Comput. 1, 409 (2011
45. Schrödinger Release 2014-2: Maestro, version 9.8, Schrödinger, LLC, New York, NY, 2014
46. Zou Y., Weis W. I., & Kobilka B. K. N-Terminal T4 Lysozyme Fusion Facilitates Crystallization of a G Protein Coupled Receptor. PLoS One 7, (2012
47. Jaakola V.-P., et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211-1217 (2008
48. Chien E. Y. T., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095 (2010
49. Wu B., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010
50. Shimamura T., et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 475, 65-70 (2011
51. Kruse A. C., et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552-556 (2012
52. Haga K., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551 (2012
53. Hanson M. A., et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851-5 (2012
54. Chun E., et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967-976 (2012
55. Dragic T., et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA. 97, 5639-5644 (2000
56. Castonguay L. A., et al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: A molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 42, 1544-1550 (2003
57. Tsamis F., et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77, 5201-5208 (2003
58. Govaerts C., et al. Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J. Biol. Chem. 278, 1892-1903 (2003
59. Nishikawa M., et al. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob. Agents Chemother. 49, 4708-4715 (2005
60. Imamura S., et al. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity. J. Med. Chem. 49, 2784-2793 (2006
61. Maeda K., et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281, 12688-12698 (2006
62. Kondru R., et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73, 789-800 (2008
63. Wang T., & Duan Y. Binding modes of CCR5-targetting HIV entry inhibitors: Partial and full antagonists. J. Mol. Graph. Model. 26, 1287-1295 (2008
64. Garcia-Perez J., et al. Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). J. Biol. Chem. 286, 33409-33421 (2011
65. Watson C., Jenkinson S., Kazmierski W., & Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67, 1268-1282 (2005
66. Rucker J., et al. Regions in ß -chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 87, 437-446 (1996
67. The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor
68. Amadei A., Linssen A. B. M., & Berendsen H. J. C. Essential dynamics of proteins. Proteins Struct. Funct. Genet. 17, 412-425 (1993
69. Shenkin P. S., & Mcdonald D. Q. Cluster Analysis of Molecular Conformations. J. Comput. Chem. 15, 899-916 (1994
70. Dogo-Isonagie C., et al. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J. Biol. Chem. 287, 15076-15086 (2012
71. Abayev M., et al. An extended CCR5 ECL2 peptide forms a helix that binds HIV-1 gp120 through non-specific hydrophobic interactions. FEBS J. 282, 1906-1921 (2015
72. Lee B., et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274, 9617-9626 (1999
73. Zhang J., et al. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies. Antimicrob. Agents Chemother. 51, 1386-1397 (2007